J 2022

Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival.

HÁJKOVÁ, Monika, Tomáš ANDRAŠINA, Petra OVESNÁ, Tomáš ROHAN, Marek DOSTÁL et. al.

Basic information

Original name

Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival.

Authors

HÁJKOVÁ, Monika (203 Czech Republic, guarantor, belonging to the institution), Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Tomáš ROHAN (203 Czech Republic, belonging to the institution), Marek DOSTÁL (203 Czech Republic, belonging to the institution), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution), Lenka OSTŘÍŽKOVÁ (203 Czech Republic), Štěpán TUČEK (203 Czech Republic), Jiří ŠEDO (203 Czech Republic) and Igor KISS (203 Czech Republic)

Edition

In vivo, KAPANDRITI, International Institute of Anticancer Research, 2022, 0258-851X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30224 Radiology, nuclear medicine and medical imaging

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.300

RIV identification code

RIV/00216224:14110/22:00127050

Organization unit

Faculty of Medicine

UT WoS

000863324700016

Keywords in English

Hepatocellular carcinoma; transarterial chemoembolization; RECIST; mRECIST; volumetric analysis

Tags

International impact, Reviewed
Změněno: 23/1/2023 12:45, Mgr. Tereza Miškechová

Abstract

V originále

Background/Aim: To evaluate the prognostic value of Response Evaluation Criteria In Solid Tumors (RECIST), modified RECIST and volumetric analysis in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). Patients and Methods: This single-center prospective cohort study included a total of 61 patients with HCC treated by transarterial chemoembolization (TACE). The response of TACE was evaluated on preprocedural and postprocedural CT by two radiologists using RECIST/mRECIST and volumetric response to treatment. Each response assessment method was used to classify the response as progressive disease, stable disease, partial response and complete response. Kaplan-Meier analysis with log-rank test was performed for each method to evaluate its ability to help predict overall survival and progression free survival. Interobserver variability and reproducibility was determined by the Pearson and Spearman correlation coefficients. Results: The median overall survival was 17.1 months and the median progression-free survival was 11.1 months. Volumetric assessment was proved to be a prognostic factor for overall survival (p<0.01) and progression-free survival (p<0.001), contrasting with RECIST and mRECIST. All three methods featured very small interobserver variability (p<0.001 for Pearson and Spearman correlation coefficients). The patients classified as having stable disease had a 3.8-fold higher risk of death than the patients classified as having a complete/partial response (HR=3.82; 95% Confidence Interval (CI)=1.32-11.02; p=0.013) and a 4.5-fold higher risk of progression (HR=4.46; 95% CI=1.72-11.61; p=0.002). Conclusion: The prognostic value of volumetric analysis in patients with HCC treated by TACE appears to be superior to RECIST and mRECIST, with a real impact in everyday practice.

Links

MUNI/A/1388/2021, interní kód MU
Name: Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě pacientů s maligním onemocněním
Investor: Masaryk University